Luca Valenti

Summary

Affiliation: Universita degli Studi di Milano, Fondazione IRCCS Ca Granda
Location: Milano, Italy
Summary:
Academic appointments:
Assistant professor, Department of Internal Medicine, Università degli Studi Milano, 2008-now

Research topic:
Hereditary hemochromatosis and iron overload diseases, nonalcoholic fatty liver disease and steatohepatitis, insulin resistance, metabolic liver diseases, genetics of liver diseases.

Clinical appointments:
Clinical assistant, Internal Medicine 1B, Fondazione Ospedale Maggiore “Ca’ Granda” Policlinico IRCCS, Milano, since 2008.
Grants:
1) PUR Università degli Studi di Milano 2008 (2008-ATE1084),
2) PUR 10% 2009 (2009-ATE0087)
3) Progetto a Concorso Fondazione Ospedale Policlinico Mangiagalli Regina Elena IRCCS 2009-2010 (Euro 40.000)
4) Bando Giovani 2007 (coordinatore nazionale progetto) Ministero della Salute e delle Politiche Sociali (GR-2007-683265)(Euro 600.000)
Publications:
1. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, Mattioli M, Levi S, Fiorelli G, Fargion S. Relationship between TNF-alpha and iron metabolism in differentiating human THP-1 cells. British Journal of Haematology. 2000;110:978-984. IF=4.438
2. Fargion S, Valenti L, Fracanzani AL, Sampietro M, Cappellini MD, Scaccabarozzi A, Soligo D, Mariani C, Fiorelli G. Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. Blood. 2000;96:3653-3655. IF=9.900
3. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood. 2001;97:3707-3712. IF=9.900
4. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. American Journal of Gastroenterology. 2001:96:2448-2455. IF=6.012
5. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in non-alcoholic fatty liver disease. Gastroenterology. 2002;122:274-280. IF=12.899
6. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, Fiorelli G, Fargion S. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Digestive and Liver Disease. 2003;35:172-178. IF=2.972
7. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease with normal glucose tolerance. Gastroenterology. 2003;124:866. IF=12.899 / 3 = 4.299 (letter with new results)
8. Dongiovanni P, Valenti L, Fracanzani AL, Taioli E, Cappellini MD, Fargion S. TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. Digestive and Liver Disease. 2003;35:596-599. IF=2.972
9. Zavaroni I, Numeroso F, Dongiovanni P, Ardigò D, Valenti L, Fracanzani AL, Valtuena S, Delsignore R, Fargion S, Reaven GM. What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volounteers? Metabolism. 2003;52:1593-1596. IF=2.426
10. Fargion S, Valenti L, Dongiovanni P, Fracanzani AL. TNF? promoter polymorphisms. in: Tumor Necrosis factor; Methods and Protocols. p 47-58. Ed: Corti A, Ghezzi P. Humana Press, Totowa (NJ, USA), 2004. Indexed for PubMed.
11. Valenti L, De Feo T, Fracanzani AL, Fatta E, Salvagnini M, Aricò S, Rossi G, Fiorelli G, Fargion S. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol and Alcoholism. 2004;39:276-280. IF=2.289
12. Bardella MT, Valenti L, Pagliari C, Peracchi M, Fracanzani AL, Farè M, Fargion S. Searching for celiac disease in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease. 2004;36:333-336. IF=2.972
13. Fargion S, Fracanzani AL, Valenti L. Treatment choices for people infected with HCV. Journal of Antimicrobial Chemotherapy. 2004;53:708-712. IF=4.352
14. Accili D, Valenti L. Turning up the heat in the fat cell. Nature Medicine. 2004;10:1168-1169. IF=27.136
15. Valenti L, Conte D, Piperno A, Dongiovanni P, Fracanzani AL, Fraquelli M, Vergani A, Gianni C, Carmagnola L, Fargion S. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary hemochromatosis. Journal of Medical Genetics. 2004;41:946-950. IF=5.751
16. Bardella MT, Valenti L, Pagliari C, Peracchi M, Fare’ M, Fracanzani AL, Fargion S. (Reply to Marignani et al.) Coeliac disease and non-alcoholic fatty liver disease. Digestive and Liver Disease. 2004;36:781-783. IF=2.972 / 5 = 0.594
17. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Iron and insulin resistance. Alimentary Pharmacology and Therapeutics. 2005;22suppl2:61-63. IF=4.357
18. Frescas D*, Valenti L*, Accili D. *equal contributors. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. Journal of Biological Chemistry. 2005;280:20589-20595. IF=5.328
19. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, Cariani E, Sangiovanni A, Tommasini A, Rossini A, Bertelli C, Fatta E, Patriarca V, Brescianini S, Stroffolini T. Association between heterozigosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Molecules and Diseases. 2005;35:27-32. IF=2.901
20. Valenti L, Pulixi E, Fracanzani AL, Dongiovanni P, Maggioni M, Orsatti A, Gianni C, Fargion S. TNFalpha genotype affects the severity of HCV chronic hepatitis by modulating TNFalpha release and insulin sensitivity. Journal of Hepatology. 2005;43:944-950. IF=7.818
21. Peracchi M, Bardella MT, Caprioli F, Massironi S, Conte D, Valenti L, Ronchi C, Beck-Peccoz P, Arosio M, Piodi L. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut. 2006;55:432-433. IF=9.357 / 3 = 3.119 (letter with new results)
22. Valenti L, Dongiovanni P, Piperno A, Maggioni M, Rametta R, Loria P, Casiraghi MA, Suigo E, Ceriani R, Remondini E, Trombini P, Fracanzani AL, Fargion S. Alpha1-antitripsin mutations in patients with NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology. 2006;44:857-864. IF=10.840
23. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia; evidence from a case control study. American Journal of Gastroenterology. 2007;102:1-8. IF=6.012
24. Valenti L, Valenti GF, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Messa PG, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. American Journal of Nephrology. 2007;27:101-107. IF=3.481
25. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, Maggioni M, Fargion S, Fracanzani AL. Relative contribution of iron genes, dysmetabolism, and HCV in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica, the Hematology Journal. 2007;92:1037-1042. IF=6.416
26. Valenti L, Dongiovanni P, Fargion S, Fracanzani AL. Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. Journal of Hepatology. 2008;48:513-514. IF=7.818 / 3 = 2.606 (letter with new results)
27. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in non alcoholic fatty liver disease. American Journal of Medicine. 2008;121:72-78. IF=4.466
28. Valenti L, Fracanzani AL, Rossi V, Rampini C, Pulixi E, Varenna M, Fargion S, Sinigaglia L. The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. Journal of Rheumatology. 2008;35:153-158. IF=3.854
29. Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. HFE mutations in Nonalcoholic fatty liver disease. Hepatology. 2008;47:1794-1795. IF=10.840 / 3 = 3.613 (letter with new results)
30. Valenti L, Valenti G, Como G, Santorelli G, Dongiovanni P, Rametta R, Fracanzani AL, Tavazzi D, Messa PG, Fargion S. HFE genotype influences erythropoiesis support requirement in hemodialysis: a prospective study. American Journal of Nephrology. 2008;28:311-316. IF=3.481
31. Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. Effect of iron depletion on insulin resistance and release in patients with HFE mutations and Nonalcoholic Fatty Liver disease. Diabetes Care. 2008;31:e18. IF=6.718 / 3 = 2.240 (letter with new results)
32. Dongiovanni P*, Valenti L*, Fracanzani AL, Gatti S, Cairo G, Fargion S. *Equal contributors. Iron depletion by deferoxamine upregulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. American Journal of Pathology. 2008;172:738-747. IF=5.673
33. Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M, Lattuada E, Roviaro G, Fargion S. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes. 2008;57:1355-1362. IF=8.505
34. Valenti L, Guido M, Dongiovanni P, Cremonesi L, Fracanzani AL, Fargion S. Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Digestive and Liver Disease. 2008;41:e17-20. IF=2.972
35. Fracanzani A, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. The risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-798. IF=10.840
36. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with Hereditary Hemochromatosis. Osteoporosis International. 2009;20:549-555. IF=4.997.
37. Fracanzani AL, Valenti L, Fargion S. Risk of severe insulin resistance in NAFLD: role of insulin resistance. (Response to Nobili et al.) Hepatology. 2008;48:2088. IF=10.840 / 5 = 2.168
38. Frcanzani AL, Valenti L, Fargion S. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. (response to Yilmaz et al.) Hepatology. 2008;49:697. IF=10.840 / 5 = 2.168
39. Valenti L, Fracanzani AL, Dongiovanni P, Vezzoli P, Fargion S. Can Nonalcoholic steatohepatitis trigger Porphyria Cutanea Tarda Clinical manifestations? Internal and Emergency Medicine. 2009;4:91-92. IF=2.371
40. Valenti L, Fracanzani AL, Fargion S. The Immunopathogenesis of alcoholic and nonalcoholic steatohepatitis. Two triggers for one disease? Seminars in Immunopathology. 2009;31:359-369. IF=5.479
41. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, Rametta R, Dongiovanni P, Messa PG, Fargion S. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clinical Journal American Society of Nephrology. 2009;8:1331-1337. IF=4.844
42. Dongiovanni P, Valenti L*, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JBS, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. *Equal contributor and corresponding author. Genetic variants regulating insulin receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. Gut. 2010;59:267-273. IF=9.357
43. Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S. Hemochromatosis in Italy in the last 30 years. Role of genetic and acquired factors. Hepatology. 2010;51:501-510. IF=10.840
44. Fracanzani AL, Piperno A, Valenti L, Fargion S. Non HFE-related hemochromatosis: the role of genetic factors. (response to Castiella et al.) Hepatology. 2010;51:1475. IF=10.840 / 5 = 2.168
45. Dongiovanni P, Fracazani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Fargion S, Valenti L. Iron dedependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. American Journal of Pathology. 2010;176:1006-1017. IF=5.673
46. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138:905-912. IF=12.899
47. Fargion S, Valenti L, Fracanzani AL. HFE mutations and cancer: expanding the clinical manifestations of hereditary iron overload. Hepatology. 2010;51:1119-1121. IF=10.840
48. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, Fargion S, Fracanzani AL. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition Metabolism and Cardiovascular Diseases. 2010; in press. IF=3.517
49. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the Patatin-like phospholipase domain containing-3 / adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209-1217. IF=10.840
50. Massironi S, Conte D, Sciola D, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M. Plasma Chromogranin A response to Octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. American Journal of Gastroenterology. 2010;105:2072-2078. IF=6.012
51. Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with nonalcoholic fatty liver disease. Journal of Hepatology. 2010;53:927-933. IF=7.818
52. Valenti L, Nobili V, Fargion S. ApoC3 gene variants, insulin resistance, and liver damage in nonalcoholic fatty liver disease. New England Journal of Medicine. 2010;863:194. Letter. IF=47.050 / 5 = 9.41
53. Valenti L, Dongiovanni P. Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Translational Research. 2010;156:226-228. IF=2.062
54. Galmozzi E, Del Menico B, Rametta R, Dongiovanni P, Fracanzani AL, Benedan L, Borroni V, Maggioni P, Fargion S, Valenti L. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis. 2010; in press. IF=3.348
55. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V. The I148M Patatin like domain containing -3 gene variant and severity of paediatric non-alcoholic fatty liver disease. Hepatology. 2010;52:1274-1280. IF=10.840
56. Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Digestive and Liver Disease. 2011;43:89-95. IF=2.972
57. Dongiovanni P, Rametta R, Fracanzani AL, Benedan L, Borroni V, Maggioni P, Maggioni M, Fargion S, Valenti L. Lack of association between Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2010:10:102. IF=1.886
58. Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Bloodletting improves insulin sensitivity and liver enzymes in nonalcoholic fatty liver disease. A propensity score-adjusted observational study. Quarterly Medical Journal. 2011;104:141-149. IF=2.627
59. Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology. 2011; in press. IF=7.818
60. Auinger A, Valenti L, Pfeuffer M, Helwig U, Herrmann J, Fracanzani AL, Dongiovanni P, Fargion S, Schrezenmeir J, Rubin D. A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with feautures of metabolic syndrome and steatosis. Hormones and Metabolic Research. 2010;42:854-859. IF=2.686
61. Valenti L, Rumi MG, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain containing-3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791-799. IF=10.840
62. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arteriosclerosis Thrombosis Vascular Biology. 2011; in press. IF=7.235
63. Manco M, Alisi A, Fernandez-Real JM, Equitani F, DeVito R, Valenti L, Nobili V. Early interplay of intra-hepatic iron and insulin resistance in children with nonalcoholic fatty liver disease. Journal of Hepatology. 2011; in press. IF=7.818
64. Valenti L, Colombo M, Fargion S. Patatin-like phospholipase domain containing-3 genotype and hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2011; in press. Letter. IF=10.840 / 5 = 2.168
65. Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JBS, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G, Daly AK, Fargion S, Day CP. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology. 2011; in press. IF=7.818
66. Valenti L, Colombo M, Fargion S. Modulation of the effect of Patatin-like phospholipase domain containing-3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. Journal of Hepatology. 2011; in press. Letter with new results. IF=7.818 / 3 = 2.606
67. Canavesi E, Valenti L. Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications. In: Hemodialysis / Book 2. Intech Open Access Publisher; 2011; in press
68. Valenti L, Dongiovanni P, Fargion S. Hepcidin and cardiovascular disease. Arteriosclerosis Thrombosis Vascular Biology. 2011 (e-Letter). IF=7.235 / 5 = 1.447

Publications

  1. ncbi request reprint Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study
    Luca Valenti
    Department of Internal Medicine, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    Am J Gastroenterol 102:1251-8. 2007
  2. pmc Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
    Paola Dongiovanni
    Department of Internal Medicine, Metabolic Liver Diseases Research Center, Universita degli Studi di Milano, Fondazione Ospedale Policlinico Ca Granda IRCCS, Milano, Italy
    BMC Gastroenterol 10:102. 2010
  3. doi request reprint Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione IRCCS Ospedale Maggiore Policlinico Ca Granda IRCCS, Milan, Italy
    Hepatology 53:791-9. 2011
  4. ncbi request reprint The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload
    Luca Valenti
    Department of Internal Medicine, Medicina Interna IB, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    J Rheumatol 35:153-8. 2008
  5. doi request reprint Iron genes, dysmetabolism and fibrosis in chronic hepatitis C
    Luca Valenti
    J Hepatol 48:513-4; author reply 514-5. 2008
  6. doi request reprint Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis
    Luca Valenti
    Department of Internal Medicine, Ospedale Maggiore Policlinico Mangiagalli Regina Elena IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, University of Milan, Milan, Italy
    Diabetes 57:1355-62. 2008
  7. doi request reprint Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation
    L Valenti
    Department of Internal Medicine, University of Milan, Milan, Italy
    Dig Liver Dis 41:e17-20. 2009
  8. doi request reprint HFE mutations in nonalcoholic fatty liver disease
    Luca Valenti
    Hepatology 47:1794-5; author reply 1795-6. 2008
  9. doi request reprint Association between iron overload and osteoporosis in patients with hereditary hemochromatosis
    L Valenti
    Dipartimento di Medicina Interna, UO Medicina Interna IB, Padiglione Granelli, Universita degli Studi di Milano, Ospedale Policlinico Mangialli e Regina Elena Fondazione IRCCS, Milan, Italy
    Osteoporos Int 20:549-55. 2009
  10. doi request reprint The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi di Milano, Padiglione Granelli, Ospedale Policlinico IRCCS, Via F Sforza 35, 20122, Milan, Italy
    Semin Immunopathol 31:359-69. 2009

Collaborators

Detail Information

Publications46

  1. ncbi request reprint Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study
    Luca Valenti
    Department of Internal Medicine, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    Am J Gastroenterol 102:1251-8. 2007
    ..Aims of this study were to define the relationship between ferritin and iron stores in patients with NAFLD, the effect of iron depletion on insulin resistance, and whether basal ferritin levels influence treatment outcome...
  2. pmc Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
    Paola Dongiovanni
    Department of Internal Medicine, Metabolic Liver Diseases Research Center, Universita degli Studi di Milano, Fondazione Ospedale Policlinico Ca Granda IRCCS, Milano, Italy
    BMC Gastroenterol 10:102. 2010
    ..Peroxisome proliferator-activated receptors (PPARs) play key roles in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)...
  3. doi request reprint Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione IRCCS Ospedale Maggiore Policlinico Ca Granda IRCCS, Milan, Italy
    Hepatology 53:791-9. 2011
    ..47, 95% CI 1.2-1.9; P = 0.002), treatment response (n = 470; OR 0.63, 95% CI 0.4-0.8; P = 0.006), and HCC occurrence (n = 325; OR 2.16, 95% CI 1.3-3.6; P = 0.002), independently of confounders...
  4. ncbi request reprint The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload
    Luca Valenti
    Department of Internal Medicine, Medicina Interna IB, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    J Rheumatol 35:153-8. 2008
    ..To analyze the clinical characteristics and genetic background associated with the presence of hand arthropathy, as determined by radiological findings, in Italian patients with hereditary hemochromatosis (HHC)...
  5. doi request reprint Iron genes, dysmetabolism and fibrosis in chronic hepatitis C
    Luca Valenti
    J Hepatol 48:513-4; author reply 514-5. 2008
  6. doi request reprint Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis
    Luca Valenti
    Department of Internal Medicine, Ospedale Maggiore Policlinico Mangiagalli Regina Elena IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, University of Milan, Milan, Italy
    Diabetes 57:1355-62. 2008
    ....
  7. doi request reprint Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation
    L Valenti
    Department of Internal Medicine, University of Milan, Milan, Italy
    Dig Liver Dis 41:e17-20. 2009
    ..In conclusion, this case report documents the recurrence of progressive liver siderosis, which recalls Ferroportin disease, associated with decreased Ferroportin-1 expression in host monocytes repopulating the donor liver...
  8. doi request reprint HFE mutations in nonalcoholic fatty liver disease
    Luca Valenti
    Hepatology 47:1794-5; author reply 1795-6. 2008
  9. doi request reprint Association between iron overload and osteoporosis in patients with hereditary hemochromatosis
    L Valenti
    Dipartimento di Medicina Interna, UO Medicina Interna IB, Padiglione Granelli, Universita degli Studi di Milano, Ospedale Policlinico Mangialli e Regina Elena Fondazione IRCCS, Milan, Italy
    Osteoporos Int 20:549-55. 2009
    ..Bone mineral density was independently associated with BMI, ALP levels, hypogonadism/menopause, and the amount of iron removed to reach depletion, but not with cirrhosis. Osteoporosis is influenced by iron overload in hemochromatosis...
  10. doi request reprint The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi di Milano, Padiglione Granelli, Ospedale Policlinico IRCCS, Via F Sforza 35, 20122, Milan, Italy
    Semin Immunopathol 31:359-69. 2009
    ..At the same time, activation of intracellular pro-inflammatory pathways by cytokines and bacterial products, inhibit insulin signaling favoring lipogenesis, metabolic alterations, and cell damage...
  11. pmc HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients
    Luca Valenti
    Center for Metabolic and Liver Diseases, Department of Internal Medicine, Universita degli Studi di Milano, Fondazione Ospedale Maggiore Policlinico MaRE IRCCS, Via F Sforza 35, 20122 Milano, Italy
    Clin J Am Soc Nephrol 4:1331-7. 2009
    ..Hepcidin-25 was evaluated by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, HFE genotype by restriction analysis...
  12. doi request reprint HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi di Milano, Ospedale Maggiore Policlinico IRCCS, Milano, Italy
    Gastroenterology 138:905-12. 2010
    ..We investigated whether these factors also contribute to the progression of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)...
  13. doi request reprint Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors
    Anna Ludovica Fracanzani
    Department of Internal Medicine, Policlinico Mangiagalli Regina Elena Hospital Foundation IRCCS, University of Milan, Italy
    Hepatology 51:501-10. 2010
    ..001). Survival did not differ across the decades in cirrhotic patients; hepatocellular carcinoma occurred similarly in HFE and non-HFE patients...
  14. doi request reprint Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors
    Sara Massironi
    Gastroenterology Unit II, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, Milan, Italy
    Am J Gastroenterol 105:2072-8. 2010
    ..Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scanty. Thus, we evaluated whether plasma CgA response to OT could predict the clinical response to SSAs...
  15. doi request reprint Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach
    Luca Valenti
    Centro Malattie Metaboliche del Fegato, Department of Internal Medicine, Universita degli Studi, Ospedale Maggiore Policlinico Ca Granda IRCCS, Milano Via F Sforza 35, Milano, Italy
    Transl Res 156:226-8. 2010
    ..These findings represent a significant step forward and should be replicated in independent series followed at tertiary centers and, thanks to the relatively low cost of the method, in populations at lower risk of liver damage...
  16. ncbi request reprint Cardiovascular disease
    Ngoc Anh Le
    Curr Opin Lipidol 18:692-5. 2007
  17. ncbi request reprint Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis
    S Fargion
    Dipartimento di Medicina Interna, Universita di Milano, Ospedale Maggiore IRCCS, Pad Granelli, Via F Sforza 35, 20122 Milan, Italy
    Blood 97:3707-12. 2001
    ..045, respectively, in homozygotes and nonhomozygotes for the C282Y mutation) and siderosis in nonhomozygotes (P =.047). Thus, TNF-alpha appears to play a role in HHC by modulating the severity of liver damage. (Blood. 2001;97:3707-3712)..
  18. ncbi request reprint Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis
    S Fargion
    Dipartimento di Medicina Interna, , Ospedale Maggiore IRCCS, Milan, Italy
    Am J Gastroenterol 96:2448-55. 2001
    ..The simultaneous disorder of iron and glucose and/or lipid metabolism, in most of the cases associated with insulin resistance, is responsible for persistent hyperferritinemia and identifies patients at risk for NASH...
  19. ncbi request reprint Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis
    L Valenti
    Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Milan, Italy
    Dig Liver Dis 35:172-8. 2003
    ..Patients with hereditary hemochromatosis, a disease characterized by progressive iron overload due, in most cases, to homozygosity for C282Y mutation in the HFE gene, have often decreased insulin sensitivity and release...
  20. ncbi request reprint TNFalpha promoter polymorphisms
    Silvia Fargion
    Department of Internal Medicine, Università delgi Studi, Milan, Italy
    Methods Mol Med 98:47-58. 2004
    ..The PCR products are then digested with specific restriction enzymes and analyzed by agarose gel electrophoresis...
  21. ncbi request reprint Treatment choices for people infected with HCV
    Silvia Fargion
    Dipartimento di Medicina Interna, Ospedale Maggiore IRCCS, Universita di Milano, Via F Sforza 35, 20122 Milan, Italy
    J Antimicrob Chemother 53:708-12. 2004
    ..Host factors influencing the rate of response are also outlined...
  22. ncbi request reprint Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes
    David Frescas
    Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032
    J Biol Chem 280:20589-95. 2005
    ..Selective modulation of the FoxO/Sirtuin interaction represents a promising therapeutic modality for metabolic disorders...
  23. ncbi request reprint Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients
    Luca Valenti
    Department of Internal Medicine, University of Milan, Policlinico Hospital IRCCS, Italy
    Alcohol Alcohol 39:276-80. 2004
    ....
  24. ncbi request reprint Turning up the heat in the fat cell
    Domenico Accili
    Nat Med 10:1168-9. 2004
  25. ncbi request reprint HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients
    Luca Valenti
    Department of Internal Medicine, University of Milano, Ospedale Policlinico Mangiagalli e Regina Elena Fondazione IRCCS, Milano, Italy
    Am J Nephrol 27:101-7. 2007
    ....
  26. ncbi request reprint Iron and insulin resistance
    S Fargion
    Dipartimento Medicina Interna, Ospedale Maggiore IRCCS, Universita di Milano, Milano, Italy
    Aliment Pharmacol Ther 22:61-3. 2005
    ..Preliminary clinical and experimental results suggest that iron can modify hepatocytes' insulin sensitivity by interfering with insulin receptor and intracellular insulin signalling...
  27. pmc Circulating ghrelin levels in patients with inflammatory bowel disease
    M Peracchi
    Gut 55:432-3. 2006
  28. ncbi request reprint Effects of distillery vinasses on vineyard yield and quality in the D.O.C "Oltrepò Pavese Pinot Nero"--Lombardy, Italy
    F Tano
    Dipartimento di Produzione Vegetale, Universita degli Studi di Milano, Via Celoria 2, 20133 Milano, Italy
    Water Sci Technol 51:199-204. 2005
    ..Highest vinasses supply improved the ripening levels of grapes increasing sugars and reducing acidity of juice. Results clearly show the possibility to use vinasses for proper vineyard fertilisation...
  29. ncbi request reprint Searching for coeliac disease in patients with non-alcoholic fatty liver disease
    M T Bardella
    Department Medical Sciences, IRCCS Ospedale Maggiore Policlinico di Milano, University of Milan, Via F Sforza, 35, 20122 Milan, Italy
    Dig Liver Dis 36:333-6. 2004
    ..Conflicting data have been reported on the prevalence of coeliac disease in non-alcoholic steatohepatitis...
  30. pmc The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis
    L Valenti
    Department of Internal Medicine, Ospedale Maggiore Policlinico IRCCS, Universita degli Studi, Pad Granelli, Via F Sforza 35, 20122 Milano, Italy
    J Med Genet 41:946-50. 2004
    ..In patients with hereditary haemochromatosis, the MnSOD genotype affects the risk of cardiomyopathy related to iron overload and possibly to other known and unknown risk factors and could represent an iron toxicity modifier gene...
  31. doi request reprint Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
    P Dongiovanni
    Università degli Studi Milano, Policlinico MaRE IRCCS Hospital, Milan, Italy
    Gut 59:267-73. 2010
    ....
  32. pmc The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis
    Serena Pelusi
    Department of Pathophysiology and Transplantation, Internal Medicine, Universita degli Studi di Milano, Fondazione IRCCS Ca Granda Ospedale Policlinico Milano, Milano, Italy
    BMC Nephrol 14:48. 2013
    ....
  33. pmc The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
    Luca Valenti
    Department of Internal Medicine, Università degli Studi Milano, UO Medicina Interna 1B, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    BMC Gastroenterol 12:111. 2012
    ..Aim of this study was to evaluate whether the I148M PNPLA3 polymorphism influences serum adiponectin in liver diseases and healthy controls...
  34. doi request reprint PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease
    Luca Valenti
    Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Section of Internal Medicine, Italy
    Dig Liver Dis 45:619-24. 2013
    ..Finally, we will examine the molecular genetics of PNPLA3 and, specifically, the theories that have been proposed to explain the function of PNPLA3 in health and disease. ..
  35. pmc Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment
    Paola Dongiovanni
    Department of Pathophysiology and Transplantation, Section Internal Medicine, Università degli Studi Milano, UO Medicina Interna1B, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy
    Curr Pharm Des 19:5219-38. 2013
    ..It is hoped that this knowledge will offer further insights into pathogenesis, suggest novel therapeutic targets, and could help guide physicians towards individualised therapy that improves clinical outcome. ..
  36. doi request reprint Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis
    Luca Valenti
    Section of Internal Medicine, Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Italy
    J Hepatol 58:399-401. 2013
    ....
  37. pmc The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease
    Luca Valenti
    Department of Pathophysiology and Transplantation, Section Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy
    PLoS ONE 7:e48804. 2012
    ..Aim of this study was to evaluate the whether the TMPRSS6 p.Ala736Val variant influences hepatic iron accumulation in a well-characterized series of Italian patients with histological NAFLD...
  38. doi request reprint Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis
    Luca Valenti
    Department of Internal Medicine, UO Medicina Interna 1B, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy
    J Hepatol 57:1319-25. 2012
    ..A736V variant of TMPRSS6 regulating hepcidin, influences iron status in the population. The aim of this study was to assess the influence of rs855791 on the penetrance and clinical expression of HH...
  39. pmc Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease
    Luca Valenti
    Universita degli Studi di Milano, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    World J Gastroenterol 18:3782-6. 2012
    ....
  40. pmc Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis
    Luca Valenti
    Universita degli Studi di Milano, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, 20122 Milano, Italy
    World J Gastroenterol 18:2813-20. 2012
    ..To investigate whether the patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism is associated with steatosis, fibrosis stage, and cirrhosis in hereditary hemochromatosis (HH)...
  41. doi request reprint Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
    ..Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC)...
  42. doi request reprint LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease
    Luca Valenti
    Department of Internal Medicine, Universita degli Studi, Ospedale Maggiore Policlinico Ca Granda IRCCS, Milan, Italy
    J Pediatr Gastroenterol Nutr 54:588-93. 2012
    ..The aim of the present study was to evaluate whether the lipin1 rs13412852 C>T polymorphism is associated with nonalcoholic steatohepatitis and fibrosis in pediatric Italian patients with nonalcoholic fatty liver disease (NAFLD)...
  43. doi request reprint The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver
    Luca Valenti
    Department of Internal Medicine, Università degli Studi Milano, UO Medicina Interna 1B, Ospedale Maggiore Ca Granda Fondazione Policlinico IRCCS, Milan, Italy
    J Hepatol 55:1409-14. 2011
    ..The aim was to assess the association between APOC3 SNPs and liver damage in Caucasian patients...
  44. doi request reprint Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations
    Luca Valenti
    Centro Malattie Metaboliche del Fegato, Department of Internal Medicine, Universita degli Studi, Ospedale Maggiore Policlinico Ca Granda IRCCS, Milano, Via F Sforza 35, 20122 Milano, Italy
    Arterioscler Thromb Vasc Biol 31:683-90. 2011
    ....
  45. doi request reprint Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease
    Luca Valenti
    Department of Internal Medicine, Università degli Studi Milano, UO Medicina Interna 1B, Fondazione Ospedale Policlinico MaRE IRCCS, Milan, Italy
    J Hepatol 53:927-33. 2010
    ....
  46. doi request reprint Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease
    L Valenti
    Center for the Study of Metabolic and Liver Diseases, Department of Internal Medicine, Università degli Studi Milano, Internal Medicine 1B, Hospital Fondazione Policlinico MaRE IRCCS, Milano, Italy
    Nutr Metab Cardiovasc Dis 21:568-75. 2011
    ..Aim of this study was to investigate the relationship between iron status and cardiovascular damage in NAFLD...